Oncolytics Biotech updates IP and trial data

Oncolytics Biotech, Inc. filed a Form 8-K to highlight two recent developments related to its cancer therapy pelareorep.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Oncolytics Biotech, Inc. filed a Form 8-K to highlight two recent developments related to its cancer therapy pelareorep. On January 8, 2026, the company issued a press release describing updates to its intellectual property portfolio and efforts to extend patent protection for pelareorep as part of its long-term value and development strategy. On January 12, 2026, it released updated clinical data from the GOBLET Cohort 4 study, which showed activity of pelareorep combined with atezolizumab in third-line anal cancer.

The company is also using this report, including the two press releases attached as Exhibits 99.1 and 99.2, as an exhibit to its existing shelf Registration Statement on Form F-3. This helps ensure that the patent and clinical updates are formally included in the broader disclosure framework the company uses for potential future securities offerings.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Oncolytics Biotech (ONCY) disclose in this Form 8-K?

Oncolytics Biotech, Inc. disclosed that it issued two press releases, one on January 8, 2026 about intellectual property updates for pelareorep and one on January 12, 2026 with updated clinical data from the GOBLET Cohort 4 study in third-line anal cancer.

What intellectual property updates did Oncolytics Biotech (ONCY) reference?

The company referenced a January 8, 2026 press release that discusses updates to its intellectual property portfolio and efforts to extend patent protection for pelareorep as part of its long-term value creation and development strategy.

What clinical data did Oncolytics Biotech (ONCY) report from the GOBLET study?

The Form 8-K notes a January 12, 2026 press release with updated clinical data from GOBLET Cohort 4, showing activity of pelareorep plus atezolizumab in patients receiving third-line treatment for anal cancer.

How does this Form 8-K relate to Oncolytics Biotech’s Form F-3 shelf registration?

The Form 8-K, including Exhibits 99.1 and 99.2, is incorporated by reference as an exhibit to Oncolytics Biotech’s Registration Statement on Form F-3 (File No. 333-289819), adding these patent and clinical updates to the disclosure used for potential future securities offerings.

Which exhibits are attached to this Oncolytics Biotech (ONCY) Form 8-K?

Exhibit 99.1 is the January 8, 2026 press release on intellectual property updates, Exhibit 99.2 is the January 12, 2026 press release on GOBLET Cohort 4 clinical data, and Exhibit 104 is the cover page interactive data file.

Does this Oncolytics Biotech (ONCY) filing report any financial statements?

The Form 8-K identifies Item 9.01 for exhibits only and lists press releases and the cover page interactive data file; it does not present financial statements in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/12/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

Oncolytics Biotech, Inc.

(Exact name of registrant as specified in its charter)

Alberta, Canada	001-38512	26-3847449
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4350 Executive Drive, Suite 325 San Diego, CA 92121	92121
(Address of principal executive offices)	(Zip Code)

(403) 670-7377
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Common shares, no par value per share	ONCY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On January 8, 2026, Oncolytics Biotech, Inc. (the “Company”) issued a press release announcing certain updates on the status of its intellectual property portfolio and ongoing efforts to extend patent protection for pelareorep as part of the Company’s long-term value creation and development strategy. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

On January 12, 2026, the Company issued a press release announcing updated clinical data from GOBLET Cohort 4 demonstrating activity of pelareorep plus atezolizumab in third-line anal cancer. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated into this Item 8.01 by reference.

In addition to any of the Company’s filings with the U.S. Securities and Exchange Commission that automatically incorporate all filings made by the Company pursuant to Sections 13(a), 13(c), 14, and 15(d) of the U.S. Securities and Exchange Act of 1934, as amended, this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is hereby incorporated by reference as an exhibit to the Company’s Registration Statement on Form F-3 (File No. 333-289819).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Press Release issued by Oncolytics Biotech, Inc., dated as of January 8, 2026.

99.2		Press Release issued by Oncolytics Biotech, Inc., dated as of January 12, 2026.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026

	ONCOLYTICS BIOTECH, INC.

	By:	/s/ Kirk Look
	Name:	Kirk Look
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Oncolytics Biotech updates IP and trial data

Rhea-AI Filing Summary

Positive

Negative